除癌胚抗原（CEA）外，糖类抗原19-9（CA 19-9）作为一种标志物用于监测结直肠癌。
CA 19-9 as a marker in addition to CEA to monitor colorectal cancer.
作者信息
Stiksma Jolanda, Grootendorst Diana C, van der Linden Peter Willem G
机构信息
Department of Oncology, Internal Medicine, Kennemer Gasthuis, Haarlem, The Netherlands; Faculty of Medicine, VU Medical Centre, Amsterdam, The Netherlands.
Department of Oncology, Internal Medicine, Kennemer Gasthuis, Haarlem, The Netherlands; Linnaeus Institute, Kennemer Gasthuis, Haarlem, The Netherlands; Landsteiner Institute, Medical Center Haaglanden, The Hague, The Netherlands.
出版信息
Clin Colorectal Cancer. 2014 Dec;13(4):239-44. doi: 10.1016/j.clcc.2014.09.004. Epub 2014 Sep 18.
BACKGROUND
Carcinoembryonic antigen is the commonly used tumor marker in patients with colorectal cancer, and CA 19-9 might be an additional marker. The aim of this retrospective study was to investigate whether CA 19-9 levels can be used to monitor the disease process in patients with colorectal cancer who had no elevated CEA levels. The secondary aim was to determine if preoperative increased levels of CEA and CA 19-9 were associated with mortality.
MATERIALS AND METHODS
Two sets of data from patients with histologically confirmed colorectal cancer, were included in a single-center study. First, patients with a minimum of 3 serial measurements of CA 19-9 and CEA tumor markers were related to the clinical course of their disease. Second, patients with preoperative levels of CEA and CA 19-9 were related to survival.
RESULTS
In patients with colorectal cancer and 3 serial measurements of tumor markers, 7.3% had only increased CA 19-9 levels without increased CEA levels, and 55.4% of the patients had an increase of CA 19-9 and CEA levels. In the patients with available preoperative markers, patients with only an increase of CA 19-9 had a significantly decreased 5-year survival compared with patients with an increase of only CEA (P = .013).
CONCLUSION
CA 19-9 can be used as additional marker to follow the disease process in patients with colorectal cancer without an increase in CEA level. Patients with preoperative increased CA 19-9 level had a poorer 5-year survival than patients with preoperative increased CEA levels.
背景
癌胚抗原是结直肠癌患者常用的肿瘤标志物，而CA 19-9可能是另一种标志物。这项回顾性研究的目的是调查CA 19-9水平是否可用于监测癌胚抗原水平未升高的结直肠癌患者的疾病进程。次要目的是确定术前癌胚抗原和CA 19-9水平升高是否与死亡率相关。
材料与方法
一项单中心研究纳入了两组经组织学确诊的结直肠癌患者的数据。第一，对至少进行了3次连续CA 19-9和癌胚抗原肿瘤标志物测量的患者，将这些测量结果与他们的疾病临床进程相关联。第二，将术前癌胚抗原和CA 19-9水平的患者与生存率相关联。
结果
在结直肠癌患者及进行了3次连续肿瘤标志物测量的患者中，7.3%的患者仅CA 19-9水平升高而癌胚抗原水平未升高，55.4%的患者CA 19-9和癌胚抗原水平均升高。在有术前标志物数据的患者中，仅CA 19-9水平升高的患者与仅癌胚抗原水平升高的患者相比，5年生存率显著降低（P = .013）。
结论
CA 19-9可作为额外的标志物，用于监测癌胚抗原水平未升高的结直肠癌患者的疾病进程。术前CA 19-9水平升高的患者5年生存率低于术前癌胚抗原水平升高的患者。
Zotero 插件